Letaplimab represents a distinct therapeutic strategy for managing complement-mediated diseases. This antibody targets C1q, a critical component of the complement cascade, effectively inhibit its first activation. https://lillisheu350463.blog5.net/92975956/letaplimab-a-innovative-clinical-method